

References

E-5

1. Burri SH, Gondi V, Brown PD, Mehta MP. The evolving role of tumor treating fields in managing glioblastoma: Guide for oncologists. *Am J Clin Oncol.* 2018;41(2):191-196.
2. Kinzel A, Abbroggi M, Varshaver M, Kirson E. Tumor treating fields for glioblastoma treatment: Patient satisfaction and compliance with the second-generation Optune® system. *Clin Med Insights Oncol.* 2019;13:1-7.
3. Hayes, Inc. Hayes Health Technology Assessment. *Tumor Treating Fields (Optune) for Treatment of Glioblastoma.* Lansdale, PA: Hayes, Inc.; 12/27/2019.
4. Benson L. Tumor treating fields technology: Alternating electric field therapy for the treatment of solid tumors. *Sem in Onc Nur.* 2018;34(2):137-150.
5. Ceresoli GL, Aerts JG, Dziadziszko R, et al. Tumor treating field in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable pleural mesothelioma (STELLAR): A multicenter, single-arm phase 2 trial. *Lancet Oncol.* 2019;20:1702-99.
6. Wang Y, Pandey M, Ballo M. Integration of tumor treating fields into the multidisciplinary management of patients with solid malignancies. *The Oncologist.* 2019;24:e1426-e1436.
7. Gkika E, Grosu AL, Mercade TM, et al. Tumor treating fields concomitant with sorafenib in advanced hepatocellular center: Results of the HEPANOVA phase II study. *Cancers* 2022;14:1568
8. National Cancer Institute (NCI). Adult central nervous system tumors treatment (PDQ) health professional version. Updated January 18, 2022; https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#cit/section_1.1. Accessed January 1, 2023.
9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Central nervous system cancers. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed January 1, 2023.

10. Regev O, Merkin V, Blumenthal DT, et al. Tumor-Treating fields for the treatment of glioblastoma: A systematic review and meta-analysis. *Neurooncol Pract.* 2021; 8(4):426-440.